FDA approves finerenone to reduce CV, renal events in patients with CKD, type 2 diabetes
The FDA approved Kerendia for reducing the risk for kidney and heart complications among adults with chronic kidney disease associated with type 2 diabetes.
In a randomized, multicenter, double-blind study, researchers compared the efficacy of Kerendia (finerenone) tablets with placebo among 5,674 patients with CKD. According to study results, 504 patients of 2,833 patients who received Kerendia experienced a composite endpoint of either a 40% reduction in kidney function, progression to kidney failure or kidney death vs. 600 patients out of 2,841 patients who received placebo. Further, cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalization occurred in 367 patients who received Kerendia vs. 420 patients who received placebo, respectively.
Kerendia received priority review as well as fast track designations.
Read more about